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Summary Objective: To determine the role of KL-6 (Krebs von den Lungen-6) in
evaluating the disease severity of pulmonary lesions in rheumatoid arthritis (RA)
compared with high resolution computed tomography (HRCT) findings.
Methods: Fifty serum KL-6 levels and HRCT images were prospectively obtained
from 47 RA patients. Eight HRCT findings were classified into five grades. Patients
were also divided into two groups according to the KL-6 threshold level and HRCT
findings were evaluated.
Results: There was a positive correlation between the serum KL-6 level and the
total CT score (r¼ 0.83). Reticular opacity most closely related to the serum KL-6
levels (r¼ 0.84). In the high KL-6 group (n¼ 10), the average CT score was markedly
increased (64.6 points) and severe honeycombing expanded into the whole lung. One
case revealed diffuse ground glass opacity. In 12 of 40 cases in the normal KL-6
group, CT scores mildly increased compared with the other cases (over 20 points).
The predominant finding of these cases could be classified into four types: (1) narrow
spread honeycombing; (2) subtle fibrosis; (3) airway diseases; and (4) dense
consolidation.
Conclusion: KL-6 is a useful marker to detect severe RA lung disease. It is also
useful to distinguish non-fibrosis from fibrosis predominant cases. However, it
sometimes could not detect early stage RA lung disease.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Pulmonary involvement, which can consist of a
wide range of pathological changes including
pulmonary fibrosis (PF), is frequently found
in patients with rheumatoid arthritis (RA)1
and is called rheumatoid lung disease (RA lung). If
it is not well controlled, respiratory failure
follows and becomes ultimately fatal.2
Therefore, it is important to detect early stage
disease and to precisely estimate its pattern and
extent.
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When evaluating the disease activity of RA lung,
arterial gas analysis, clinical symptoms, chest
radiograph, lactate dehydrogenase, and pulmonary
function test have been used. However, these
markers are not always sensitive and are sometimes
nonspecific.3 KL-6 (Krebs von den Lungen-6), a new
serum indicator for PF discovered by Kohno et al. in
1985,4 has been reported to correlate with clinical
manifestation 5,6 and has been investigated in RA
lung. Oyama et al. reported that serum KL-6 levels
showed no other significant correlation with para-
meters of disease activity such as erythrocyte
sedimentation rate, C-reactive protein, IgM-rheu-
matoid factor, and IgG-rheumatoid factor in RA.7
Further, it was not influenced by extrapulmonary
inflammation, and abnormal elevation of serum KL-
6 levels strongly indicated the complication of
active interstitial pneumonitis. They concluded
that KL-6 was a valuable indicator in the manage-
ment of the disease activity of RA lung.
On the other hand, high resolution computed
tomography (HRCT) also provides useful informa-
tion to assess the RA lung.8,9 Previous studies
described its radiologic–pathologic correlation,
and there is a general consensus that HRCT findings
are highly correlated with pathological findings.1,10
Although some studies have investigated the
relation between pulmonary function and chest
radiographic findings in RA lung,3 correlation of
KL-6 with HRCT has not been fully investigated. In
this study, we compared serum KL-6 levels with
HRCT findings in RA patients to determine a role for
KL-6 in evaluating disease severity.
Subjects and methods
The subjects of this prospective study were 47
consecutive patients with RA (33 females and 14
males; aged 37–79 years; mean, 63.5), seen at our
hospital between January and June 1999. All
patients were clinically and serologically diagnosed
as RA by an orthopedist and underwent treatment
according to their symptoms over a period of 6
months. All fulfilled the revised criteria of the
American Rheumatism Association for RA.11 Pa-
tients who had a clinical history of another lung
disease, or had other complications like drug-
induced pneumonitis as the side effects of treat-
ment for RA were excluded from this study.
Fifty HRCT scans and KL-6 examinations were
prospectively obtained from the 47 patients who
gave informed consent prior to the examinations.
Three patients had two HRCT scans and KL-6
examinations, each separated by intervals of 2–10
weeks. All KL-6 examinations were performed
within 2 weeks before or after HRCT. Serum KL-6
levels were measured by a sandwich type of
enzyme-linked immunosorbent assay using a KL-6
antibody kit (ED046; Eisai; Tokyo, Japan). The
threshold level for serum KL-6 was determined at
520 unit/ml; level reported by Kohno et al. pre-
viously.4 On evaluation, patients were classified
into two groups according to their serum KL-6 level;
a normal KL-6 group: KL-6o520U/ml and a high
KL-6 group: KL-6X520U/ml.
HRCT evaluation
HRCTwas performed using a Somatom Plus S CTunit
(Siemens; Erlangen, Germany), with 2-mm collima-
tion at 15-mm intervals at end inspiration from the
lung apices to the bases. Expiratory HRCT scans at
three selected levels were also obtained (aortic
arch, hila, and lower lobes). All images were
reconstructed with a high-spatial frequency algo-
rithm, and photographed at window widths of
1500H.U. and window levels of 600H.U.
Six HRCT images at end inspiration, two slices
each from the upper, middle and lower lung, were
selected and analyzed. Two experienced chest
radiologists, blinded to the clinical information,
evaluated the HRCT images focusing on 8 findings:
(1) nodular opacities, defined as well marginated
nodules including micronodules, nodules and con-
glomerate masses; (2) bronchial dilatation and wall
thickening, defined as abnormally dilated bronchial
divisions with or without bronchial wall thickening
including thickened bronchovascular bundle and
traction bronchiectasis as well as tubular bronch-
iectasis; (3) pleural thickening; (4) reticular opa-
cities, defined as reticular network of lines
including intralobular reticular opacities and
honeycombing; (5) linear opacities, defined as thin
linear opacities of irregular thickness of 1–3mm,
including interlobular septal thickening, nonseptal
line, subpleural curvilinear shadow, and band
shadow; (6) increased lung opacities, defined as
increased attenuation of lung parenchyma includ-
ing ground glass opacities (GGO) and parenchymal
opacification; (7) lung cysts, defined as thin-walled
air spaces; and (8) emphysema, defined as diffusely
decreased pulmonary attenuation. Air trapping on
expiratory scans was also referred to when evalu-
ating the findings numbers (2) and (8).
To determine the distribution of parenchymal
abnormalities, we used a slight modification of the
visual estimation method described by Davies
et al.12 The findings were visually classified into
five grades according to their extent. Each CT slice
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level was divided into four areas according to a
horizontal and a vertical line drawn by the first
observer and scored in a semiquantitative manner
as follows: 0¼ absent; 1¼ less than 25% involved;
2¼ 25–50% involved; 3¼ 50–75% involved; and
4¼ greater than 75% involved. The final judgment
was reached by consensus. Scores were added to
obtain total scores for each patient and the cases
were graded into three types according to their
total CT scores: normal¼ 0–20 points; mildly
abnormal¼ 21–40 points; remarkably abnormal
441 points.
Data were expressed as means7standard devia-
tion. The correlation between the CTscores and the
serum KL-6 levels was calculated using Pearson’s
correlation coefficients.
Results
The serum KL-6 levels ranged from 145 to 1863
U/ml, with a median value of 443.0734.5 U/ml.
Total CT scores ranged from 0 to 84 with a median
value of 23.6724.6 points. There was a positive
correlation between total CT scores and serum KL-6
levels (r¼ 0.83, Po0.001) (Fig. 1a).
Table 1 reveals the correlation coefficient be-
tween serum KL-6 levels and CT scores of the eight
findings. Six findings, excepting nodular opacity and
emphysema, had positive correlation. Especially
reticular opacity (r¼ 0.84; Fig. 1b), pleural thick-
ening (r¼ 0.79), increased lung opacity (r¼ 0.70;
Fig. 1c), lung cyst (r¼ 0.67), and linear opacity
(r¼ 0.60; Fig. 1d) had a high correlation with serum
KL-6 levels.
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Figure 1 Plots of correlations between serum KL-6 levels and HRCT score. HRCT score has good correlation with serum
KL-6: (a) total HRCTscore (r¼ 0.83); (b) HRCTscore of reticular opacity (r¼ 0.84); (c) increased lung opacity (r¼ 0.70);
and (d) linear opacity (r¼ 0.60).
Table 1 Correlation between serum KL-6 level
and HRCT score.
Correlation
coefficient
Total CT score 0.83n
Reticular opacity 0.84n
Pleural thickening 0.79n
Increased lung opacity 0.70n
Lung cyst 0.67n
Linear opacity 0.60n
Bronchial dilatation,
wall thickening
0.52n
Emphysema 0.12
Nodular opacity 0.08
nPo0.01
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Ten cases were classified into the high KL-6 group
(Table 2); with 9 of the 10 revealing remarkably
abnormal CT findings having total CT scores over 60
points. The main abnormal HRCT finding of this
group was honeycombing expanded into the whole
lung and was mainly comprised of reticular opa-
cities, pleural thickening, increased lung opacities,
and linear opacities (Fig. 2). Only one case had
diffusely distributed GGO and a mixture of honey-
combing (Fig. 3).
Forty cases were classified into the normal KL-6
group; 28 had normal HRCT findings, whereas 12
had abnormal CT findings. Eleven cases revealed
mildly abnormal CT findings with CT scores of 21
through 40 points, and one revealed remarkably
abnormal CT findings with CT score of 41 points.
In these cases, HRCT revealed four main abnormal
patterns: narrow spread honeycombing with
subpleural linear shadows (Fig. 4); subtle fibrosis
consist of a nonseptal line, septal thickening,
intralobular reticular opacities, and localized
GGO (Fig. 5); airway disease such as bulla,
emphysema, and bronchial dilatation and wall
thickening (Fig. 6); and patchy air-space consolida-
tion associated with GGO within a small area
(Fig. 7).
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Table 2 Average serum KL-6 level and total HRCT score in each group.
Serum KL-6 level (U/ml) No. of the cases according to HRCT score
0–20 21–40 41–60 61
High KL-6 group (n¼ 10) 1102.47440.7 1 0 0 9
Normal KL-6 group (n¼ 40) 278.17106.5 28 11 1 0
Figure 2 A 48-year-old woman in the high KL-6 group
(serum KL-6 level¼ 1092, total HRCT score¼ 65.5). HRCT
shows bilateral extensive honeycombing with traction
bronchiectasis. This finding expands into the whole lung.
Figure 3 A 56-year-old man in the high KL-6 group
(serum KL-6 level¼ 1086, total HRCT score¼ 83.5). HRCT
demonstrates bilateral diffuse ground glass opacities.
Traction bronchiectasis and mild honeycombing are also
present. This patient died one month after this examina-
tion.
Figure 4 A 65-year-old woman in the normal KL-6 group
(serum KL-6 level¼ 479, total HRCT score¼ 41). HRCT
demonstrates narrow spread honeycombing predomi-
nantly in subpleural region in the bilateral lung bases.
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Discussion
RA lung is one of the major extraarticular compli-
cations in patients with RA, and shows various types
of pulmonary lesions such as necrobiotic nodule,
pleuritis, bronchiolitis obliterans organizing pneu-
monia (BOOP), bronchiolitis obliterans (BO), arter-
itis, lymphoid hyperplasia, and PF.1,10,13 Above all,
bronchiectasis and interstitial lung involvement are
the most common CT features. Though in previous
reports the prevalence has been shown to vary
according to the diagnostic criteria and method
used, it is known from recent HRCT studies, that
bronchiectasis is the most frequent abnormality,
reaching up to 40% of cases.14,15 On the other hand,
the frequency of PF is also reported to be as high as
around 40%.16,17 Some patients with RA lung
develop severe respiratory failure caused by
extensive fibrosis; while it usually progresses
slowly, accelerated deterioration also occurs.2
Therefore, it is necessary to precisely evaluate
disease activity and to detect early stage lesions.
KL-6, a serum indicator of disease activity that
has recently been utilized, is a mucinous high-
molecular weight glycoprotein, which is strongly
expressed on proliferated type 2 alveolar pneumo-
cytes and epithelial cells.4 In alveolitis, inflamma-
tory cells damage basement membrane and
epithelial cells of the alveolar wall, followed by
regenerated type 2 alveolar pneumocytes appear-
ing over the basement membrane. KL-6 may be
released into blood by the injured epithelial cells
within the lung compartment.18 Measurements of
these molecules in peripheral blood may reflect the
degree of leakage from alveolus to the capillarie.
Previous reports have revealed KL-6 to be a
useful marker reflecting the severity of pulmonary
fibroproductive lesions.19 It can be used to evaluate
disease activity in various lung diseases besides
idiopathic pulmonary fibrosis such as radiation
pneumonitis and pneumocystis carinii pneumonia,
which cause fibrotic lesions.20 KL-6 has also been
reported to be useful for detecting active PF in RA
Iung.7,21,22 In this study, there was a positive
correlation between serum KL-6 levels and total
HRCT scores. Furthermore, 9 of the 10 cases with
increased serum KL-6 levels had remarkably high CT
scores of over 41 points. On the other hand, CT
scores of 39 of the 40 cases with normal KL-6 level
were under 40 points. As previous reports have
mentioned, high serum KL-6 level is sufficient
evidence to diagnose that there is severe fibrotic
lesions of RA lung.
In clinical cases, when RA patient are seen to
have a high serum KL-6 level, HRCT can reveal
severe honeycombing or diffusely expanded GGO.
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Figure 5 A 47-year-old woman in the normal KL-6 group
(serum KL-6 level¼ 348, total HRCT score¼ 31.5). HRCT
demonstrates bilateral increased interstitial markings,
mainly nonseptal line, in the lower lung zone correspond-
ing to subtle fibrosis.
Figure 6 A 55-year-old woman in the normal KL-6 group
(serum KL-6 level¼ 258, total HRCT score¼ 28). There is
marked bronchiolectasis and wall thickening.
Figure 7 A 71-year-old woman in the normal KL-6 group
(serum KL-6 level¼ 202, total HRCT score¼ 29). There is
localized ground-glass opacity with peripheral dense
consolidation in the right lower lung.
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In our study the HRCT finding that best correlated
with serum KL-6 level was reticular opacity. And in
four of the five cases with extremely high KL-6
levels (over 1000U/ml), honeycombing involved
the whole lung associated with pleural thickening
and linear opacities. Reticular opacity reveals
ongoing fibrotic process; while in early stage
fibrosis, fine reticulation can be observed in the
lower lung zones. As fibrosis develops, reticular
opacities progress to peripheral honeycombing,
which then expands from the periphery to the
central lung.23 This process progresses slowly and is
often irreversible; a high KL-6 level could reflect
this slow progression.
On the other hand, increased lung opacity was
the third most correlated HRCT findings with serum
KL-6 level. In four of the five cases with extremely
high KL-6 levels, it was observed as a mixed pattern
with reticular opacities. In another case, GGO,
which has been known to be a valuable indicator for
disease activity, was recognized throughout the
lung. In early stage fibrosis very fine fibrosis is often
observed as localized GGO,23 and in the stage of
accelerated deterioration diffuse GGO is observed
reflecting active alveolitis. GGO is also reported to
correlate with pathological disease activity or the
response to treatment.24 In our study the patient
with diffuse GGO died 1 month after examination
and suggested to be in the condition of accelerated
deterioration. High KL-6 level could also reflect
rapid progression.
When a RA patient is seen to have a normal KL-6
level, HRCT generally will reveal normal findings,
but sometimes abnormal findings can be revealed.
In the present study, HRCT described four main
abnormal patterns in normal KL-6 level patients.
The presence of narrow spread honeycombing and
subtle fibrosis suggested mild PF. Although the
finding of early stage RA lung is not well described,
it has been reported to resemble that of early stage
PF.25 Thus, a mild PF pattern might correspond
early stage RA lung. The presence of airway
diseases suggested a BO lesion of RA lung, while
dense consolidation within a small area suggested a
BOOP lesion of RA lung. These two patterns
correspond to nonfibrotic lesions of RA lung.2
Increases of the serum KL-6 level has been reported
not only in PF but also in pulmonary alveolar
proteinosis, sarcoidosis and pulmonary tuberculo-
sis.26–28 Various lung diseases cause proliferation of
type 2 alveolar pneumocytes, epithelial cell injury,
and alveolar-capillary permeability changes, which
cause an increase of the serum KL-6 level. In RA
lung, the wide spectrum of pathologic patterns are
recognized as reflecting the various types of
pulmonary lesions, except fibrosis. However, HRCT
findings representing those patterns had less
correlation with the serum KL-6 level. This result
suggests that KL-6 is useful to distinguish non-
fibrosis predominant cases from fibrosis predomi-
nant cases.
Unfortunately, this study still remains an attempt
to acquire preliminary data that will provide a
foundation for future studies. For a better objec-
tive evaluation of the disease activity, it will be
necessary to examine changes of CT findings within
longer periods. In this study, due to our short
research period, serial CT studies were obtained in
just three patients in the high KL-6 group. In two of
the three cases HRCT findings did not change even
if KL-6 levels remained high. In the other case,
serum KL-6 decreased as HRCT findings improved
after treatment. There are many reports which
have described that the serum KL-6 level decreased
after successful treatment for accelerated dete-
rioration.20,26 KL-6 measurement might be useful to
follow-up the disease activity. Further study invol-
ving larger numbers of patients is necessary, which
focuses on how the HRCT findings change after 1 to
several years as KL-6 change.
Consequently, in cases with a high serum KL-6
level, HRCT reveals severe fibrotic changes at a
high frequency. In cases with normal serum KL-6
levels, HRCT generally reveals normal findings,
though sometimes narrow spread fibrosis, airway
diseases, and BOOP can be revealed. KL-6 seems to
be difficult to detect subtle fibrotic changes.
However, KL-6 is useful to distinguish nonfibrosis
from fibrosis predominant cases. KL-6 is a con-
venient, objective, and sensitive marker to esti-
mate disease severity; nevertheless, it is ancillary
tool that can help screen the RA lung. These two
examinations, KL-6 and HRCT, play supplemental
roles in the evaluation of disease severity.
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